Contineum Therapeutics Announces Completion of Enrollment for Phase 1b PET Trial of PIPE-791 in Healthy Volunteers and PrMS Patients

Reuters

2025/06/25

Contineum <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Completion of Enrollment for Phase 1b PET Trial of PIPE-791 in Healthy Volunteers and PrMS Patients

Contineum Therapeutics Inc. has provided an update on its Phase 1b positron emission tomography $(PET.AU)$ trial of PIPE-791, an antagonist targeting the lysophosphatidic acid 1 (LPA1) receptor. The clinical-stage biopharmaceutical company, focusing on neuroscience, inflammation, and immunology therapies, has completed enrollment of healthy volunteers and progressive multiple sclerosis (PrMS) cohorts. The ongoing trial aims to assess the correlation between pharmacokinetics and LPA1 receptor occupancy in these groups, with screening and enrollment of idiopathic pulmonary fibrosis $(IPF.UK)$ patients still in progress. The company plans to present topline data from the fully enrolled cohorts in the third quarter of 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Contineum Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250625697950) on June 25, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2546217093"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2546217093\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2546217093?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-25 20:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2546217093","market":"nz","top_or_hot":-1,"title":"Contineum Therapeutics Announces Completion of Enrollment for Phase 1b PET Trial of PIPE-791 in Healthy Volunteers and PrMS Patients","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Contineum <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Completion of Enrollment for Phase 1b PET Trial of PIPE-791 in Healthy Volunteers and PrMS Patients\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Contineum Therapeutics Inc. has provided an update on its Phase 1b positron emission tomography <a href=\"https://laohu8.com/S/PET.AU\">$(PET.AU)$</a> trial of PIPE-791, an antagonist targeting the lysophosphatidic acid 1 (LPA1) receptor. The clinical-stage biopharmaceutical company, focusing on neuroscience, inflammation, and immunology therapies, has completed enrollment of healthy volunteers and progressive multiple sclerosis (PrMS) cohorts. The ongoing trial aims to assess the correlation between pharmacokinetics and LPA1 receptor occupancy in these groups, with screening and enrollment of idiopathic pulmonary fibrosis <a href=\"https://laohu8.com/S/IPF.UK\">$(IPF.UK)$</a> patients still in progress. The company plans to present topline data from the fully enrolled cohorts in the third quarter of 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Contineum Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250625697950) on June 25, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Contineum Therapeutics Announces Completion of Enrollment for Phase 1b PET Trial of PIPE-791 in Healthy Volunteers and PrMS Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nContineum Therapeutics Announces Completion of Enrollment for Phase 1b PET Trial of PIPE-791 in Healthy Volunteers and PrMS Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-25 20:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Contineum <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Completion of Enrollment for Phase 1b PET Trial of PIPE-791 in Healthy Volunteers and PrMS Patients\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Contineum Therapeutics Inc. has provided an update on its Phase 1b positron emission tomography <a href=\"https://laohu8.com/S/PET.AU\">$(PET.AU)$</a> trial of PIPE-791, an antagonist targeting the lysophosphatidic acid 1 (LPA1) receptor. The clinical-stage biopharmaceutical company, focusing on neuroscience, inflammation, and immunology therapies, has completed enrollment of healthy volunteers and progressive multiple sclerosis (PrMS) cohorts. The ongoing trial aims to assess the correlation between pharmacokinetics and LPA1 receptor occupancy in these groups, with screening and enrollment of idiopathic pulmonary fibrosis <a href=\"https://laohu8.com/S/IPF.UK\">$(IPF.UK)$</a> patients still in progress. The company plans to present topline data from the fully enrolled cohorts in the third quarter of 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Contineum Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250625697950) on June 25, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CTNM","symbol_name":"Contineum Therapeutics, INC.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250625:nNDL6Rmqg0:1","article_id":"2546217093","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2546217093","pubTimestamp":1750853720,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Contineum Therapeutics Announces Completion of Enrollment for Phase 1b PET Trial of PIPE-791 in Healthy Volunteers and PrMS Patients. Contineum Therapeutics Inc. has provided an update on its Phase 1b positron emission tomography  trial of PIPE-791, an antagonist targeting the lysophosphatidic acid 1  receptor. The clinical-stage biopharmaceutical company, focusing on neuroscience, inflammation, and immunology therapies, has completed enrollment of healthy volunteers and progressive multiple sclerosis  cohorts. The ongoing trial aims to assess the correlation between pharmacokinetics and LPA1 receptor occupancy in these groups, with screening and enrollment of idiopathic pulmonary fibrosis  patients still in progress. The company plans to present topline data from the fully enrolled cohorts in the third quarter of 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CTNM":"Contineum Therapeutics, INC.","BK4007":"制药"},"translate_title":"Contineum Therapeutics宣布完成PIPE-791在健康志愿者和PrMS患者中的1b期PET试验入组","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CTNM":0.9},"content_text":"Contineum Therapeutics Announces Completion of Enrollment for Phase 1b PET Trial of PIPE-791 in Healthy Volunteers and PrMS Patients\n    \n\n        Contineum Therapeutics Inc. has provided an update on its Phase 1b positron emission tomography $(PET.AU)$ trial of PIPE-791, an antagonist targeting the lysophosphatidic acid 1 (LPA1) receptor. The clinical-stage biopharmaceutical company, focusing on neuroscience, inflammation, and immunology therapies, has completed enrollment of healthy volunteers and progressive multiple sclerosis (PrMS) cohorts. The ongoing trial aims to assess the correlation between pharmacokinetics and LPA1 receptor occupancy in these groups, with screening and enrollment of idiopathic pulmonary fibrosis $(IPF.UK)$ patients still in progress. The company plans to present topline data from the fully enrolled cohorts in the third quarter of 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Contineum Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250625697950) on June 25, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}